Efficacy of Unani drugs in Obesity
- Conditions
- Health Condition 1: E668- Other obesity
- Registration Number
- CTRI/2021/03/032025
- Lead Sponsor
- ational Institute of Unani Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Patients having Body Mass Index 25-29.9 kg/m2
2. Patients with or without mild to moderate stage 1 obesity related complications such as
-Hypertriglyceridemia with fasting serum triglyceride level 150-400 mg/dl
-Prediabetes (Hyperglycemia) with FBS <=125mg/dL, PPBS <=199mg/dL
-Prehypertension with blood pressure <140/90 mm Hg and treated with CCB and/or β blockers
3. Patients who will give consent and are able to do follow up
1. Patients below 20 and above 50 years
2. Patients having BMI <25 and >29.9 kg/m2
3. Fasting serum triglyceride level >400 mg/dl
4. Blood pressure >=140/90 mm Hg or treated with diuretics and ACE inhibitors
5. Fasting blood sugar >=126 mg/dL, PPBS >=200 mg/dL or treated with oral hypoglycaemic agents or insulin
6. Patient with hypothyroidism, any other serious systemic illness or known case of IHD
7. Psychiatric disorders including major depression, schizophrenia, bulimia, alcohol abuse or substance abuse
8. Use of drugs, herbs or supplements known to significantly affect body weight (anti-obesity agents, anti-depressants, antipsychotics, anti-epileptic drugs, glucocorticoids, laxatives, oral contraceptives, female hormones etc.) within the past 3 months
9. History of bariatric surgery or abdominal adhesion after surgery
10. Pregnant and lactating women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method BMI, WC, WHRTimepoint: 0th, 20th, 40th and 60th day
- Secondary Outcome Measures
Name Time Method Improvement in Quality of lifeTimepoint: 0th, 20th, 40th and 60th day;Stage 1 Obesity related complicationsTimepoint: 0th and 60th day